Latest Headlines

1. Invivoscribe Announces Updated Reimbursement For The LeukoStrat CDx FLT3 Mutation Assay To Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible For VANFLYTA In Japan 5/25/2023

   Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan's Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA® (quizartinib).

2. Oneoncology Presents Abstracts At ASCO Highlighting Importance Of Increasing NGS Testing 5/25/2023

   At the 2023 ASCO annual meeting, investigators from OneOncology's clinical team will present Oral Abstracts using real-world data to evidence better health outcomes when advanced Non-Small Cell Lung Cancer (aNCSLC) patients receive biomarker testing, including Next-Generation Sequencing (NGS) testing, to determine whether the patient has an actionable driver oncogene for a targeted therapy, even if a non-targeted therapy has begun, as well as the current inequities in receiving NGS testing between White, Black, and Latinx populations.

3. IQVIA & (RED) Announce Groundbreaking Partnership To Support Laboratory System Strengthening 5/25/2023

   IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives.

4. Domus Diagnostics Moves Closer To Delivering Affordable At-Home Molecular Test For COVID-19, Flu-A, Flu-B And RSV 5/24/2023

   Domus Diagnostics , a U.S.-based point-of-care diagnostics company, has received an award from the National Institutes of Health (NIH) to further develop its point-of-care nucleic acid amplification and detection test for simultaneous identification of COVID-19, Flu-A, Flu-B, and RSV.

5. Knobbe Martens Secures Complete Victory For Spectrum Solutions In Covid-19 Testing PTAB Dispute 5/24/2023

   A team from Knobbe Martens led by Ali Razai secured a decisive, complete and unprecedented victory for Spectrum Solutions, LLC in inter partes review (IPR) challenges of five separate patents owned by Longhorn Vaccines & Diagnostics.

6. Synthace Combines ChatGPT And Digital Experiments In First Step Toward A True AI Scientist 5/24/2023

   Synthace, creators of the world’s first digital experiment platform for life science R&D, today announces the successful integration of their platform with OpenAI’s ChatGPT.

7. Roche Introduces Navify® Sample Tracking For Labs To Track Patient Test Samples Before Even Reaching Lab Premises 5/22/2023
8. Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd 5/22/2023

   Freenome, a privately held biotech company, announced today it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.

9. ACLA And 33 Provider Organizations Urge Congress To Protect Americans’ Access To Essential Laboratory Tests 5/22/2023

   The American Clinical Laboratory Association has joined with more than 30 health care provider organizations to urge House and Senate leadership to protect patient access to clinical laboratory services by passing the Saving Access to Laboratory Services Act (SALSA / H.R. 2377 / S. 1000) this year.

10. Thermo Fisher Scientific Announces FDA Clearance Of Breakthrough Immunoassays To Aid In The Risk Assessment Of Preeclampsia 5/19/2023

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers, the first and only immunoassays to receive breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, a severe pregnancy complication.